Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer

Abiraterone may suppress androgens that stimulate breast cancer growth. We conducted a biomarker analysis of circulating tumor cells (CTCs), formalin-fixed paraffin-embedded tissues (FFPETs), and serum samples from postmenopausal estrogen receptor (ER)+ breast cancer patients to identify subgroups w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical Cancer Research 2016-12, Vol.22 (24), p.6002-6009
Hauptverfasser: Li, Weimin, O'Shaughnessy, Joyce A, Hayes, Daniel F, Campone, Mario, Bondarenko, Igor, Zbarskaya, Irina, Brain, Etienne, Stenina, Marina, Ivanova, Olga, Graas, Marie-Pascale, Neven, Patrick, Ricci, Deborah S, Griffin, Thomas W, Kheoh, Thian, Yu, Margaret K, Gormley, Michael, Martin, Jason, Schaffer, Michael, Zelinsky, Kathy, De Porre, Peter, Johnston, Stephen R.D
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abiraterone may suppress androgens that stimulate breast cancer growth. We conducted a biomarker analysis of circulating tumor cells (CTCs), formalin-fixed paraffin-embedded tissues (FFPETs), and serum samples from postmenopausal estrogen receptor (ER)+ breast cancer patients to identify subgroups with differential abiraterone sensitivity.
ISSN:1078-0432